NAI114373: A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitali

Project: Research project

Project Details

StatusFinished
Effective start/end date10/21/1010/31/15

Funding

  • GlaxoSmithKline plc (NAI114373)